| Market Cap | 34M | P/E | - | EPS this Y | 82.80% | Ern Qtrly Grth | - |
| Income | -15.21M | Forward P/E | -0.63 | EPS next Y | 1.40% | 50D Avg Chg | -8.00% |
| Sales | 278k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -25.00% |
| Dividend | N/A | Price/Book | 3.58 | EPS next 5Y | - | 52W High Chg | -65.00% |
| Recommedations | 1.70 | Quick Ratio | 2.30 | Shares Outstanding | 5.58M | 52W Low Chg | 34.00% |
| Insider Own | 15.53% | ROA | -74.66% | Shares Float | 35.14M | Beta | -0.26 |
| Inst Own | 8.19% | ROE | -802.80% | Shares Shorted/Prior | 22.05K/45.42K | Price | 1.23 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 214,493 | Target Price | 10.85 |
| Oper. Margin | -2,974.68% | Earnings Date | Dec 17 | Volume | 18,325 | Change | -2.38% |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.